The patent linkage system  has been implemented in Taiwan since 2019. To assist pharmaceutical companies in their understanding of the operation of the system and the application of its relevant policies, the competent authority, the Food and Drug Administration of the Ministry of Health and Welfare (hereinafter the “FDA”), has held several “Pharmaceutical Patent Linkage System Promotion & Legal Education” seminars this year. Mr. Albert Su and Mr. Tim Tsai, Partner and Associate of the Formosan Brothers Attorneys-in-Law respectively, were invited as the guest speakers for the August and September seminars in Taipei, Taichung & Tainan.

In each of the seminars, Mr. Su and Mr. Tsai introduced the foundational concepts in pharmaceutical patents, relevant regulations, and current issues that arise from patent linkage litigations in Taiwan, including preservation and investigation of evidence. They also provided recommendations regarding the patent layout strategy throughout the development and launching life cycle of new drugs and generic drugs. The presentations for the three seminars have been uploaded to the FDA website for viewing in the following links:

Taipei: https://www.fda.gov.tw/tc/includes/GetFile.ashx?id=f637326697355456577

Taichung: https://www.fda.gov.tw/tc/includes/GetFile.ashx?id=f637339485606085055

Tainan: https://www.fda.gov.tw/tc/includes/GetFile.ashx?id=f637365408274679463

If you have any suggestions or questions regarding the patent linkage system or related topics, please do not hesitate to contact us. We look forward to providing you with comprehensive legal services.

Formosan Brothers, Attorneys-at-Law

Yvonne Lin, Esq., Director/Managing Partner  yvonne@mail.fblaw.com.tw

Albert Su, Esq., Partner/Patent Attorney yowlunsu@mail.fblaw.com.tw

Tim Tsai, Esq., Associate  timtsai@mail.fblaw.com.tw